Summary

Lung Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Lung Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lung Infections, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/universit...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Drugs In Development, 2021, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Drugs In Development, 2021, pr...

Summary

GlobalData's clinical trial report, “Acute Lung Injury Global Clinical Trials Review, H2, 2018" provides an overview of Acute Lung Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lung Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain compe...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Pipeline Review, H2 2018, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.

Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Pipeline Review, H2 201...

Summary

GlobalData's clinical trial report, “Lung Transplant Rejection Global Clinical Trials Review, H2, 2017" provides an overview of Lung Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Lung Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter ...

Summary

GlobalData's clinical trial report, “Lung Infections Global Clinical Trials Review, H2, 2017" provides an overview of Lung Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Lung Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive...

Summary

GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H2, 2017" provides an overview of Lung Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Lung Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.<...

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Lung Injury Overview 10
Therapeutics Development 11
Pipeline Products for Acute Lung Injury - Overview 11
Pipeline Products for Acute Lung Injury - Comparative Analysis 12
Acute Lung Injury - Therapeutics under Development by Companies 13
Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 15
Acute Lung Injury - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Acute Lung Injury - Products under Development by Companies 19
Acute Lung Injury - Products under Investigation by Universities/Institutes 21
Acute Lung Injury - Companies Involved in Therapeutics Development 22
Altor BioScience Corp 22
Asklepion Pharmaceuticals LLC 23
Commence Bio Inc 24
CompleGen Inc 25
GlaxoSmithKline Plc 26
Histocell SL 27
Lung Therapeutics Inc 28
Navigen Pharmaceuticals Inc 29
Quark Pharmaceuticals Inc 30<...

Summary

GlobalData's clinical trial report, “Acute Lung Injury Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lung Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lung Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain compe...

Summary

GlobalData has released its pharma report, “Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing NSCLC Market. The report identifies and analyses the key companies shaping and driving the global NSCLC market. The report provides insight into the competitive NSCLC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for NSCLC
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of NSCLC sector through market impact analysis, future market s...

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.

As a drug class, immunotherapeutics are projected to contribute the most to the US market expansion. As a result, both these drug classes are expected to take patient share away from branded chemotherapy, a class that will contract as a whole at a negative CAGR of 18.4%. The growth of the IO drug class will be fueled by the increasing use of immunotherapies across histologies and lines of therapy in NSCLC. The use of PD-1 checkpoint inhibitors in first-line therapy of N...

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.

In 2015, the NSCLC market in the 5EU was an estimated $1.53B. This growth is fueled by the increasing use of immunotherapies across histologies and lines of therapy in NSCLC. Particularly, the use of PD-1 checkpoint inhibitors in first-line therapy of NSCLC is expected to take away significant sales from conventional chemotherapies that are typically used in the first line. Merck & Co.’s Keytruda is the current front-runner in the first-line setting, as it’s already...

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.

In 2015, the NSCLC market in Japan was an estimated $981M. This growth is fueled by the increasing use of immunotherapies across histologies and lines of therapy in NSCLC. The use of PD-1 checkpoint inhibitors in first-line therapy of NSCLC is expected to take away significant sales from conventional chemotherapies that are typically used in the first line. The recent failure of Opdivo monotherapy in 5% or more of PD-L1+ patients in the first-line could further help Tec...

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.

In 2015, the NSCLC market in China was an estimated $445M. This growth is fueled by the use of immunotherapies across histologies and lines of therapy in NSCLC, as well as increased access to drugs. Currently, PD-1 inhibitors have not yet launched in China, and thus, there is significant untapped potential for this class of drugs, both in the first- and second-line settings in the Chinese market.

*This is an on-demand report and will be delivered within 24 hrs. (...

Summary

Global Markets Direct’s, ‘Lung Transplantation - Pipeline Review, H1 2016’, provides an overview of the Lung Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lung Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lung Transplantation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC f...

Summary

GlobalData's clinical trial report, “Pulmonary Embolism Global Clinical Trials Review, H1, 2016" provides an overview of Pulmonary Embolism clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Embolism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain co...

Summary

Global Markets Direct’s, ‘Emphysema - Pipeline Review, H1 2016’, provides an overview of the Emphysema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Emphysema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Emphysema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured ...

Summary

Global Markets Direct’s, ‘Bronchiectasis - Pipeline Review, H1 2016’, provides an overview of the Bronchiectasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor present...